Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond.

Slides:



Advertisements
Similar presentations
A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.
Advertisements

Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation  Sarah J. Kizilbash, Clifford E. Kashtan,
Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns 
Accelerated Bone Mineral Density Loss Occurs with Similar Incidence and Severity, But with Different Risk Factors, after Autologous versus Allogeneic.
Admission of Hematopoietic Cell Transplantation Patients to the Intensive Care Unit at the Pontificia Universidad Católica de Chile Hospital  Karen Escobar,
Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report.
Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.
Vaccination of Children following Allogeneic Stem Cell Transplantation
Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma  Taewoong Choi, Murali K. Kodali, Wen-Kai Weng 
Reduced-Intensity Conditioning Hematopoietic Cell Transplantation Is an Effective Treatment for Patients with SLAM-Associated Protein Deficiency/X-linked.
Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.
Allogeneic Stem Cell Transplantation in Myelofibrosis
A 15-Year Analysis of Early and Late Autologous Hematopoietic Stem Cell Transplant in Relapsed, Aggressive, Transformed, and Nontransformed Follicular.
Hematopoietic Stem Cell Transplantation for Refractory or Recurrent Non-Hodgkin Lymphoma in Children and Adolescents  Thomas G. Gross, Gregory A. Hale,
Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns 
Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation 
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular.
Efficacy of Reduced-Intensity Allogeneic Stem Cell Transplantation in Chemotherapy- Refractory Non-Hodgkin Lymphoma  Robert M. Dean, Daniel H. Fowler,
Alternate Donor Hematopoietic Cell Transplantation (HCT) in Non-Hodgkin Lymphoma Using Lower Intensity Conditioning: A Report from the CIBMTR  Gregory.
Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?  Jason W. Chien, Keith M. Sullivan  Biology.
Betty T. Tran, Abigail Halperin, Jason W. Chien 
Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma  Marcel P. Devetten,
J. J. Nietfeld, Marcelo C. Pasquini, Brent R
Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J
New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation  Anita D'Souza,
Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma  Peter Dreger, Ginna.
Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation  Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport 
The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.
Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation  Navneet.
Relapse of Lymphoma after Allogeneic Hematopoietic Cell Transplantation: Management Strategies and Outcome  Kitsada Wudhikarn, Claudio G. Brunstein, Veronika.
B Cells and Transplantation: An Educational Resource
Outcomes of Patients 65 Years and Older with Non-Hodgkin Lymphoma Receiving Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.
Cutaneous Complications in Hematopoietic Cell Transplant Recipients: Impact of Biopsy on Patient Management  Oana Paun, Tycel Phillips, Pingfu Fu, Roberto.
Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation 
Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting.
Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma  John Kuruvilla, Gregory Pond, Richard.
Kamal Kant Singh Abbi, Junting Zheng, Sean M
Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma  Christopher Parrish, Amin Rahemtulla, Jim.
High-Dose Carmustine, Etoposide, and Cyclophosphamide Followed by Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma  Lisa Y. Law,
Elevated Ferritin Is Associated with Relapse after Autologous Hematopoietic Stem Cell Transplantation for Lymphoma  Anuj Mahindra, Brian Bolwell, Ronald.
Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck 
Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation  Willis H. Navarro, Fausto R.
Allogeneic Hematopoietic Cell Transplantation in Human Immunodeficiency Virus– Positive Patients with Hematologic Disorders: A Report from the Center for.
Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence  Keshav.
Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation  Sarah J. Kizilbash, Clifford E. Kashtan,
The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group  Amber B. Clemmons,
Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data  Brent R. Logan, Mei-Jie Zhang,
Pauline Damien, David S. Allan 
Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation  Mohammed M. Elayan, Justin G.
What is quality in a transplant program?
Athanasios Anagnostopoulos, Parameswaran N. Hari, Waleska S
Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match  Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,
Blood and Marrow Transplant Handbook
Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older.
Koen van Besien, Jeanette Carreras, Philip J. Bierman, Brent R
Comorbidities, Not Age, Impact Outcomes in Autologous Stem Cell Transplant for Relapsed Non-Hodgkin Lymphoma  Tanya M. Wildes, Kristan M. Augustin, Diane.
A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome  Peggy A. Wu,
Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse 
Early Lymphocyte Recovery Predicts Superior Survival after Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma: A Prospective Study  Luis F.
Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow.
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
Treatment versus Transplant for Challenging Hematologic Disorders
Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma  Ivan Aksentijevich,
Simplified Validated Prognostic Model for Progression-Free Survival after Autologous Transplantation for Hodgkin Lymphoma∗  Theresa Hahn, Philip L. McCarthy,
Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation  Marco Mielcarek, Barry.
Mary Eapen  Biology of Blood and Marrow Transplantation 
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience  Andy I. Chen, Alex McMillan,
Presentation transcript:

Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond First Complete Response or First Partial Response  Marcie R. Tomblyn, Marian Ewell, Christopher Bredeson, Brad S. Kahl, Stacey A. Goodman, Mary M. Horowitz, Julie M. Vose, Robert S. Negrin, Ginna G. Laport  Biology of Blood and Marrow Transplantation  Volume 17, Issue 7, Pages 1051-1057 (July 2011) DOI: 10.1016/j.bbmt.2010.11.004 Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 OS (A) and PFS (B) after allogeneic and autologous HCT for FL. Biology of Blood and Marrow Transplantation 2011 17, 1051-1057DOI: (10.1016/j.bbmt.2010.11.004) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.